Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Age \>18 years~2. Histologically confirmed diagnosis of DLBCL~3. Tumour tissue for central pathology review and correlative studies had to be provided.~4. Participants must had:~   * relapsed and/or refractory disease~  * at least one bidimensionally measurable, PET positive disease site (transverse diameter of ≥1.5 cm and perpendicular diameter of ≥1.0 cm at baseline)~  * received at least one, but no more than three previous systemic regimens for the treatment of DLBCL and one therapy line must had included a CD20-targeted therapy~  * Eastern Cooperative Oncology Group 0 to 2~5. Participants were not considered in the opinion of the investigator eligible, or participants unwilling to undergo intensive salvage therapy including ASCT~6. Participants had to meet the following laboratory criteria at screening:~   * absolute neutrophil count ≥1.5 × 10˄9/L~  * platelet count ≥90 × 10˄9/L~  * total serum bilirubin ≤2.5 × ULN or ≤5 × ULN in cases of Glibert's Syndrome or liver involvement by lymphoma~  * alanine transaminase, aspartate aminotransferase and alkaline phosphatase ≤3 × ULN or \<5 × ULN in cases of liver involvement~  * serum creatinine clearance ≥60 mL/minute~7. Females of childbearing potential (FCBP) must:~   * not be pregnant~  * refrain from breastfeeding and donating blood or oocytes~  * agreed to ongoing pregnancy testing~  * committed to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception~8. Males (if sexually active with a FCBP) had to~   * use an effective barrier method of contraception~  * refrain from donating blood or sperm~9. In the opinion of the investigator the participants had to:~   * be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events~  * be able to understand, give written informed consent and comply with all study-related procedures, medication use, and evaluations~  * had no history of noncompliance in relation to medical regimens or not be considered potentially unreliable and/or uncooperative~  * be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and gave written acknowledgement of this.~Major Exclusion Criteria:~1. Participants who had:~   * other histological type of lymphoma~  * primary refractory DLBCL~  * a history of double/triple hit genetics~2. Participants who had, within 14 days prior to Day 1 dosing:~   * not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy~  * underwent major surgery or suffered from significant traumatic injury~  * received live vaccines.~  * required parenteral antimicrobial therapy for active, intercurrent infections~3. Participants who:~   * had, in the opinion of the investigator, not recovered sufficiently from the adverse toxic effects of prior therapies~  * were previously treated with CD19-targeted therapy or immunomodulatory drugs (IMiDs)® (e.g., thalidomide, LEN)~  * had a history of hypersensitivity to compounds of similar biological or chemical composition to MOR00208, IMiDs® and/or the excipients contained in the study drug formulations~  * had undergone ASCT within the period ≤ 3 months prior to the signing of the Informed Consent Form. Patients who had a more distant history of ASCT had to exhibit full haematological recovery before enrolment into the study~  * had undergone previous allogenic stem cell transplantation~  * had a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or were at a high risk for a thromboembolic event in the opinion of the investigator and who were not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period~  * concurrently used other anti-cancer or experimental treatments~4. Prior history of malignancies other than DLBCL, unless the participant had been free of the disease for ≥5 years prior to screening.~5. Participants with:~   * positive hepatitis B and/or C serology.~  * known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)~  * CNS lymphoma involvement~  * history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromised the participant's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tafasitamab (MOR00208) + lenalidomide (LEN) (Type: EXPERIMENTAL): MOR00208:~MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.~Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.~LEN:~Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.~On days when both study drugs were given together, LEN was administered prior to MOR00208.

Based on this trial design, predict the completion outcome and termination type (if applicable).